Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--Authors' reply

Lancet. 2014 Sep 20;384(9948):1097-8. doi: 10.1016/S0140-6736(14)61674-3.

Authors

Rury R Holman¹, Harald Sourij², Robert M Califf³

Affiliations

¹ Diabetes Trials Unit, Churchill Hospital, University of Oxford, Oxford, Headington OX3 7LJ, UK. Electronic address: rury.holman@dtu.ox.ac.uk.
² Diabetes Trials Unit, Churchill Hospital, University of Oxford, Oxford, Headington OX3 7LJ, UK; Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria.
³ Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.

PMID: 25241719
DOI: 10.1016/S0140-6736(14)61674-3

No abstract available

Publication types

Letter
Comment

MeSH terms

Diabetes Mellitus, Type 2 / drug therapy*
Diabetic Angiopathies / drug therapy*
Humans
Hypoglycemic Agents / therapeutic use*

Substances

Hypoglycemic Agents